^
Association details:
| Biomarker: | HRD + BRCA2 mutation |
|---|---|
| Cancer: | Peritoneal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/08/2023
Excerpt:
Olaparib with bevacizumab is recommended, within its marketing authorisation, for maintenance treatment of high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose cancer...is homologous recombination deficiency (HRD) positive (defined as having either a BRCA1 or BRCA2 mutation, or genomic instability).
